FDA Approves Dupixent (dupilumab) for Children Aged 6 to 11 Years with Moderate-to-Severe Atopic…
Regeneron Pharmaceuticals, Inc. and Sanofi announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for children aged 6 to 11 years with…
Read More...
Read More...